| Added by | tchardes |
|---|---|
| Group name | EquipeELC |
| Item Type | Journal Article |
| Title | Long-Term Results with Everolimus in Advanced Hormone Receptor Positive Breast Cancer in a Multicenter National Real-World Observational Study |
| Creator | François-Martin et al. |
| Author | Hélène François-Martin |
| Author | Barbara Pistilli |
| Author | Christelle Levy |
| Author | Jean-Sébastien Frenel |
| Author | Séverine Guiu |
| Author | Marie-Ange Mouret-Reynier |
| Author | Audrey Mailliez |
| Author | Jean-Christophe Eymard |
| Author | Thierry Petit |
| Author | Mony Ung |
| Author | Isabelle Desmoulins |
| Author | Paule Augereau |
| Author | Thomas Bachelot |
| Author | Lionel Uwer |
| Author | Marc Debled |
| Author | Jean-Marc Ferrero |
| Author | Florian Clatot |
| Author | Anthony Goncalves |
| Author | Sylvie Chabaud |
| Author | Paul Cottu |
| Abstract | Everolimus is the first oral targeted therapy widely used in advanced HR+/HER2- breast cancer. We sought to evaluate the impact of everolimus-based therapy on overall survival in the ESME-MBC database, a national metastatic breast cancer cohort that collects retrospective data using clinical trial-like methodology including quality assessments. We compared 1693 patients having received everolimus to 5928 patients not exposed to everolimus in the same period. Overall survival was evaluated according to treatment line, and a propensity score with the inverse probability of treatment weighting method was built to adjust for differences between groups. Crude and landmark overall survival analyses were all compatible with a benefit from everolimus-based therapy. Adjusted hazard ratios for overall survival were 0.34 (95% CI: 0.16-0.72, p = 0.0054), 0.34 (95% CI: 0.22-0.52, p < 0.0001), and 0.23 (95% CI: 0.14-0.36, p < 0.0001) for patients treated with everolimus in line 1, 2, and 3 and beyond, respectively. No clinically relevant benefit on progression-free survival was observed. Causes for everolimus discontinuation were progressive disease (56.2%), adverse events (27.7%), and other miscellaneous reasons. Despite the limitations inherent to such retrospective studies, these results suggest that adding everolimus-based therapy to the therapeutic sequences in patients with advanced HR+/HER2- breast cancer may favorably affect overall survival. |
| Publication | Cancers |
| Volume | 15 |
| Issue | 4 |
| Pages | 1191 |
| Date | 2023-02-13 |
| Journal Abbr | Cancers (Basel) |
| Language | eng |
| DOI | 10.3390/cancers15041191 |
| ISSN | 2072-6694 |
| Library Catalog | PubMed |
| Extra | PMID: 36831532 PMCID: PMC9954606 |
| Tags | advanced luminal breast cancer, clinic, overall survival |
| Date Added | 2023/03/02 - 14:58:20 |
| Date Modified | 2023/03/02 - 14:58:44 |
| Notes and Attachments | PubMed entry (Attachment) Texte intégral (Attachment) |
Institut de Recherche en Cancérologie de
